Cannabinoids offer modest relief for MS-related muscle stiffness
Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials.
AI Summary
This systematic review examined whether cannabinoids can reduce spasticity—muscle stiffness and involuntary contractions—in people with multiple sclerosis. The review included 27 randomized studies involving more than 3,000 participants and evaluated THC:CBD extracts, other cannabis extracts, isolated cannabinoids, and smoked cannabis.
Across 7 studies included in a direct comparison with placebo, THC:CBD extracts produced a modest improvement in patient-reported spasticity. The review found that side effects were common but usually mild to moderate, while serious adverse events were rare. However, the overall certainty of the evidence was low, and the studies varied substantially in their methods and clinical characteristics. The authors conclude that cannabinoids may be considered cautiously as an add-on treatment, with appropriate safety monitoring, rather than as a replacement for established therapies.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More THC research papers you might find interesting.
Small lab study finds cannabis affected simulated driving and confidence
A lab method measures 17 cannabinoids across five hemp product types
A single-center study finds varied care and no recurrence in follow-up
Explore More Research
Stay informed about the latest cannabis science.